Kode Technology – Journal paper Index

Categorisation index for 101 journal publications · Reference numbers 001–101

Use this index to find papers by material, technique, biological target, application or disease. All numbers refer to the journal-paper section of the Kode Technology bibliography (8 November 2026); conference abstracts and proceedings are excluded. Papers intentionally appear under multiple headings.

Interpretation: Entries are subject-matter tags based on the supplied bibliography, not a claim that every included paper experimentally used Kode/FSL constructs. Some cited papers concern related biology, comparators or reviews. More specific assay tags are conservative where the supplied citation does not describe full methods.

CATEGORY / LOOKUP TOPIC	JOURNAL PAPER NUMBERS
1. SURFACE OR BIOLOGICAL SUBSTRATE	
Engineered red cells / kodecytes	007, 008, 011, 013, 026, 028, 031, 036, 038, 039, 042, 049, 050, 058, 061, 067, 068, 069, 071, 072, 076, 079, 085, 086, 087, 091, 094, 095, 096, 097, 099, 100, 101
Red-cell biology, transfusion and blood-group genetics	013, 051, 053, 054, 055, 062, 072, 077, 083, 086, 095, 096, 097, 100, 101
Enveloped virions, pseudovirions and VLPs	001, 002, 009, 019, 021, 024, 037, 046, 047, 052, 056, 063, 064, 066, 073, 075, 080, 081, 084, 090, 091, 092, 093, 098
Cell membranes and engineered cell-surface glycans	004, 010, 018, 027, 033, 058, 062, 069, 088, 089, 091, 101
Liposomes, artificial membranes, GUVs and protocells	010, 016, 017, 032, 035, 040, 041, 057, 059, 060, 078
Nanoparticles, supramolecular aggregates and lipid carriers	012, 016, 022, 041, 059, 065
Solid substrates: paper, microplates, silicon and other supports	021, 047, 050, 065, 070, 071, 079, 091
Nanofibres and surface-functionalised materials	065, 070
Endothelial cells, microvesicles and vascular interfaces	012, 015, 018
Cancer cells, tumour microenvironment or tumour models	022, 025, 035, 045, 056, 059
Bacteria, bacterial toxin systems and host interactions	011, 023, 029, 032

CATEGORY / LOOKUP TOPIC	JOURNAL PAPER NUMBERS
Zebrafish and other cell-migration models	089
2. CONSTRUCT COMPOSITION AND MOLECULAR TARGETS	
FSL/Kode platform, general surface-modification protocols	039, 048, 049, 050, 074, 088, 091, 100, 101
Glycan-bearing and synthetic glycolipid constructs	005, 006, 007, 010, 013, 014, 018, 022, 038, 043, 044, 045, 058, 065, 069, 070, 071, 074, 079, 088, 098, 101
ABO A/B antigens and ABH glycans	007, 010, 013, 018, 042, 044, 058, 061, 068, 069, 079, 086, 087, 096, 097, 100, 101
Lewis glycans and Lewis-specific reagents	069, 071
Forssman / FORS1 glycans	043, 051, 053, 072, 083
MNS/Miltenberger/MUT/Mur peptide antigens	055, 094, 095, 099
SARS-CoV-2 peptide antigens and FSL peptide bioconjugates	003, 008, 026, 028, 031, 034, 036
Syphilis (TmpA) peptide antigens	011
CMV peptide antigen constructs	085
Rhamnose (L-Rha) epitopes or rhamnose conjugates	005, 022
Alpha-Gal / AGI-134 glycolipid immunotherapy	045
Heparan sulfate-related lipid conjugates	006
Gb3 / globotriaosylceramide / Pk-related systems	022, 023, 025, 035, 040, 078, 093, 098
Biotin / FSL-biotin / avidin–streptavidin chemistry	001, 002, 009, 012, 021, 024, 037, 041, 046, 047, 050, 052, 063, 064, 066, 073, 075, 080, 081, 091
Fluorophore and radiolabel functional heads	056, 067, 080, 089, 091, 092
Lipid anchor, spacer and membrane-insertion variables	004, 016, 027, 033, 041, 047, 074, 084, 088, 091, 101

3. DIAGNOSTIC ASSAY AND MEASUREMENT FORMAT	
Red-cell serology and antigen–antibody assays	007, 008, 011, 013, 026, 028, 031, 036, 038, 039, 042, 049, 055, 061, 068, 069, 071, 072, 079, 085, 086, 087, 094, 095, 099, 100
Haemagglutination, column agglutination and blood-bank platforms	008, 011, 026, 028, 031, 036, 039, 042, 049, 061, 071, 079, 094, 095, 099

3. DIAGNOSTIC ASSAY AND MEASUREMENT FORMAT	
ABO typing, subgroup simulation and antibody quantification	007, 010, 013, 042, 049, 058, 061, 068, 079, 086, 087, 096, 097, 100, 101
Extended blood-group antigen/antibody detection (Lewis/MNS/FORS)	043, 051, 053, 055, 069, 071, 072, 083, 094, 095, 099
SARS-CoV-2 antibody diagnostics and population surveillance	003, 008, 020, 026, 028, 031, 034, 036
Syphilis antibody diagnostics	011
CMV antibody or IVIG Fc-function assays	085
Solid-phase ELISA/EIA and receptor-binding plate assays	001, 002, 009, 024, 034, 037, 046, 052, 063, 064, 066, 073, 075, 081, 093, 098
Biotin–streptavidin capture, immobilisation or magnetic separation	001, 002, 009, 012, 021, 024, 037, 046, 047, 050, 052, 063, 064, 066, 073, 075, 081
Microslit membranes, solid-state biosensors or flow-based detection	021
Quartz crystal microbalance / membrane adsorption assays	047
Flow cytometry or fluorescence-based cell/virion detection	056, 067, 080, 087, 089, 091, 092
Optical/intravital imaging and cellular/viral tracking	012, 056, 067, 080, 089, 091, 092
Radioisotope labelling and in vivo nuclear imaging	092
Haemolysis, complement-fixation and Fc-function measurement	006, 014, 054, 068, 085, 096
Laboratory QC, proficiency testing and reference reagents	039, 049, 061, 076, 085, 100
Education, simulated panels and reaction grading	026, 076
4. VIRUSES, INFECTIONS AND VIRAL MECHANISMS	
Direct virion biotinylation, modification or capture	001, 002, 009, 024, 037, 046, 047, 052, 063, 064, 066, 073, 075, 080, 081, 091, 092
Viral entry, glycoprotein–receptor interactions	001, 002, 019, 024, 037, 046, 052, 063, 064, 066, 073, 075, 081, 090, 093, 098
Viral neutralisation, antibodies or vaccine studies	009, 019, 024, 037, 046, 063, 064, 066, 084
Hantaviruses, PCDH1 and related pseudotyped viruses	001, 002, 009, 019, 024, 046, 052, 073
Ebola, Sudan and other filoviruses	037, 063, 064, 066, 075, 081

3. DIAGNOSTIC ASSAY AND MEASUREMENT FORMAT	
Vesicular stomatitis virus and VSV pseudotypes	009, 037, 046, 052, 056, 073, 084, 092, 093
Influenza virus labelling	080
HIV-1, viral microbicides and Gb3-based inhibition	093, 098
SARS-CoV-2 infection, vaccines and serology	003, 008, 020, 026, 028, 031, 034, 036
Measles and DC-SIGN-mediated infection	090
Cytomegalovirus antibody detection	085
Vaccinia or intact-virus capture sensors	021
Bacterial pathogens, Shiga/Shigella toxins, Treponema	011, 022, 023, 029, 032
Parasitic pathogens and innate pathogen-pattern responses	082
5. GLYCOBIOLOGY AND IMMUNOLOGICAL MECHANISMS	
ABO/ABH antigen presentation and fine specificity	007, 010, 013, 042, 044, 058, 068, 069, 079, 087, 101
Lewis epitope and monoclonal/polyclonal antibody specificity	069, 071
Forssman system and anti-FORS1 antibodies	043, 051, 053, 072, 083
Natural anti-glycan antibodies, xenoantigens and epitope mapping	005, 007, 013, 014, 038, 051, 053, 062, 072
Lectin–glycan binding, surface recognition and adhesion	015, 018, 025, 032, 035, 040, 057, 060, 078
Complement activation/inhibition and haemolytic pathways	006, 014, 038, 045, 068, 085, 096
Antigen/epitope structure, molecular recognition and modelling	003, 005, 007, 010, 013, 014, 024, 062, 064, 071, 079
Lipid rafts, glycolipid domains and membrane organisation	004, 017, 027, 033, 040, 041, 047, 059, 060, 078
Innate immunity, dendritic cells and pathogen-response pathways	045, 054, 082, 090
Alloantibody prevalence, immunogenicity and blood-group genetics	051, 053, 055, 077, 083, 095
6. THERAPEUTIC AND TRANSLATIONAL APPLICATIONS	

3. DIAGNOSTIC ASSAY AND MEASUREMENT FORMAT	
Cancer immunotherapy, tumour targeting or in situ vaccination	022, 025, 035, 045, 056, 059
AGI-134 / alpha-Gal local immunotherapy	045
Oncolytic virotherapy, virion shielding and biodistribution	056, 084, 092
HIV microbicide and viral infection inhibition	093, 098
Shigella/Shiga-toxin targeting or toxin-neutralisation	022, 023, 029
Cardiovascular disease, atherosclerosis and vascular biology	012, 018
Nanoparticle drug delivery, carrier formulation and uptake	012, 016, 017, 032, 059
ABO-incompatible transplantation or transfusion	042, 086, 096, 097
Vaccine immunogens and viral protective immunity	009, 019, 024, 046, 064
In vivo animal studies, tissue imaging and physiological testing	009, 012, 019, 022, 025, 045, 056, 084, 089, 090, 092, 096, 097
7. METHODS AND REVIEWS	
Chemical synthesis, glycan preparation or conjugation methods	006, 010, 013, 016, 022, 027, 034, 041, 043, 044, 058, 065, 069, 074, 088, 094, 098, 099, 101
Spontaneous membrane insertion, stability and release kinetics	004, 027, 033, 050, 067, 074, 080, 088, 091, 101
Self-assembly, supramers and nanoparticle physical structure	016, 017, 032, 041, 047, 059, 060, 078
Biophysical force, membrane mechanics and receptor recognition	004, 010, 016, 017, 032, 033, 040, 047, 057, 060, 062, 078
Printing, coating and solid-phase surface functionalisation	021, 050, 065, 070, 071, 079
General reviews, technical overviews or methodological surveys	030, 039, 044, 048, 049, 074, 100
Position pieces, translational perspectives and surveillance concepts	020, 030, 048, 049, 100
Related research/clinical context (not an independent FSL-use claim)	017, 023, 025, 029, 030, 032, 035, 040, 051, 053, 054, 055, 059, 060, 062, 077, 078, 082, 083, 090